Incorrect password
evipedia.ai Suggest Edit

Selank for Health & Longevity

Evidence Review created on 04/21/2026 using AI4L / Opus 4.7

Also known as: TP-7, Selanc, Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP

Motivation

Selank is a short synthetic peptide developed in Russia as a stabilized version of tuftsin, a small immune-signaling fragment released naturally from antibodies in the body. Adding a three-amino-acid tail (proline-glycine-proline) extends the half-life of the parent molecule and adds calming and cognition-supporting effects not seen with tuftsin alone. Since 2009 it has been approved in Russia as a nasal spray for generalized anxiety, and it has drawn growing interest in longevity and nootropic communities for reported calming and focus-sharpening effects without the sedation or dependence linked to conventional anti-anxiety drugs.

Selank sits at the intersection of three areas that matter for long-term health: anxiety and stress physiology, immune signaling, and brain resilience. Russian clinical trials describe anxiety reduction comparable to benzodiazepines but with an entirely different mechanism, and preclinical work points to effects on neurotrophic signaling, inflammatory tone, and even antiviral immunity. The trials are small and have not been independently repeated outside Russia, which shapes how the evidence should be read.

This review examines what is currently known about Selank’s proposed mechanisms, the evidence for calming, cognitive, and immune effects, its safety profile, and the sourcing and protocol considerations relevant to anyone evaluating it as a health-optimization tool.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overview content discussing Selank and its role as an anxiolytic, nootropic, and immunomodulatory peptide.

  • Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity - Vyunova et al., 2018

    Narrative research article from the Institute of Molecular Genetics that lays out Selank’s molecular mechanism of action as a positive allosteric modulator of GABA-A receptors, including radioligand binding evidence differentiating it from classical benzodiazepines — a useful primer on why Selank is described as non-sedating.

  • Selank Peptide – Benefits, Safety and Buying Advice - Innerbody

    Consumer-facing overview covering origins, mechanism, Russian clinical evidence for anxiolytic and nootropic effects, safety profile, regulatory status, and practical purchasing considerations, with balanced treatment of both benefits and the limits of the current evidence base.

  • Tuftsin – Properties and Analogs - Siebert et al., 2017

    Narrative review of tuftsin and its synthetic analogs, including Selank, that explains the structural rationale for the Pro-Gly-Pro extension, covers the immunomodulatory mechanisms, and frames the therapeutic potential of tuftsin-derived peptides.

  • Selank Peptide Dosage, Benefits & Side Effects - Jay Campbell

    Practitioner-style, long-form overview written for health-optimization readers, summarizing Selank’s reported effects on anxiety, focus, and stress resilience, with practical discussion of intranasal and subcutaneous dosing, cycling, and the quality-control concerns around research-grade peptides.

  • Peptides in Mental Health: A New Frontier - Lea Lis

    Psychiatrist-authored piece describing clinical use of Selank and related peptides in mental health practice, including intranasal administration and the correlation between Selank treatment and leu-enkephalin elevation — a useful clinical perspective for readers coming from a Western medicine frame.

Note: Dedicated content discussing Selank in substantial depth could not be located on the platforms of the prioritized experts (Rhonda Patrick / foundmyfitness.com, Peter Attia / peterattiamd.com, Andrew Huberman / hubermanlab.com, Chris Kresser / chriskresser.com, Life Extension Magazine / lifeextension.com). This appears to reflect Selank’s niche, regionally concentrated literature rather than any oversight.

Grokipedia

Selank

Dedicated Grokipedia entry covering Selank’s origins as a tuftsin analog developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, its anxiolytic, nootropic, and neuroprotective properties, its Russian approval for generalized anxiety disorder, and the main administration routes (intranasal and subcutaneous).

Examine

No dedicated article on Selank was found on Examine.com. Examine primarily covers dietary supplements and common natural compounds and does not typically include synthetic research peptides that lack regulatory approval outside Russia.

ConsumerLab

No dedicated article on Selank was found on ConsumerLab.com. ConsumerLab focuses on independently testing commercially available dietary supplements and does not typically cover synthetic research peptides such as Selank.

Systematic Reviews

No systematic reviews or meta-analyses for Selank were found on PubMed as of 04/21/2026.

Mechanism of Action

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built by adding a C-terminal Pro-Gly-Pro tripeptide to tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory fragment released from the Fc region of immunoglobulin G. The Pro-Gly-Pro tail dramatically slows enzymatic degradation while preserving tuftsin’s biological activity and adding new central nervous system (CNS, the brain and spinal cord) effects.

Conflict of interest note on the evidence base: Nearly all published Selank research originates from a small, interconnected set of Russian institutions — the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences, the V.V. Zakusov Research Institute of Pharmacology, and the commercial manufacturer NPO Peptogen (which markets the approved product under IMG supervision). These groups have a direct institutional and commercial interest in Selank’s adoption; most mechanistic, preclinical, and clinical studies share authorship, funding, and material-supply ties with them. This structural conflict of interest applies to essentially every Selank primary source cited below and should be kept in mind when weighing the evidence.

Selank acts through several overlapping pathways:

  • GABAergic modulation: Selank acts as a positive allosteric modulator of GABA-A receptors, enhancing the binding affinity of GABA (gamma-aminobutyric acid, the brain’s main inhibitory neurotransmitter) at its receptor. Radioligand binding work shows that Selank increases [³H]GABA binding in a concentration-dependent and subtype-selective way at a site that appears distinct from the benzodiazepine site — consistent with the clinical observation that Selank is anxiolytic without producing sedation or muscle relaxation. Selank also alters expression of GABA-A receptor subunit genes and of the GABA transporters GAT1 and GAT3 (proteins responsible for reuptaking GABA from the synapse) in the hippocampus.
  • BDNF upregulation: Intranasal Selank rapidly increases BDNF (brain-derived neurotrophic factor, a protein that supports the growth, survival, and plasticity of neurons) messenger RNA in the hippocampus and prefrontal cortex in rodents, and normalizes ethanol-induced disruptions in BDNF signaling.
  • Serotonergic and dopaminergic modulation: Selank alters serotonin and dopamine turnover in the brain and changes expression of dopamine D1 and D2 receptor genes (Drd1a and Drd2), contributing to its antidepressant-like and nootropic effects.
  • Enkephalin system modulation: Selank inhibits enzymes that degrade enkephalins (endogenous opioid-like peptides involved in pain and mood regulation), raising their effective half-life. In clinical work on generalized anxiety disorder (GAD, a condition of persistent excessive worry), Selank treatment increased leu-enkephalin levels, and the increase correlated with anxiety reduction.
  • Immunomodulation and cytokine regulation: As a tuftsin analog, Selank retains and extends tuftsin’s immune effects. It alters expression of more than 35 genes encoding chemokines, cytokines, and their receptors in the spleen; under chronic social stress it reduces pro-inflammatory cytokines IL-1β (interleukin-1 beta, a key inflammatory signaling protein), IL-6 (interleukin-6, an inflammation-regulating cytokine), and TNF-α (tumor necrosis factor alpha, a pro-inflammatory cytokine) while restoring anti-inflammatory IL-4 (interleukin-4, a cytokine that promotes anti-inflammatory responses).
  • Interferon induction and antiviral activity: Selank induces gene expression of IFN-α (interferon-alpha, a signaling protein activating antiviral defenses) and in cell culture has suppressed replication of influenza A (H3N2) when given preventively.
  • Functional brain connectivity: Functional magnetic resonance imaging (fMRI, a brain-imaging technique measuring regional activity by blood-oxygen signals) in healthy volunteers showed that Selank changes resting-state connectivity between the right amygdala (a region central to fear and anxiety processing) and right temporal cortex within 5 – 20 minutes of administration.

Key pharmacological properties: Selank’s plasma half-life is very short (approximately 2 – 10 minutes) because the peptide is rapidly degraded by circulating peptidases. Functional effects on anxiety and cognition, however, persist for roughly 12 – 24 hours after a single dose, reflecting downstream gene-expression and neurotrophic changes rather than sustained receptor occupancy. Intranasal bioavailability is approximately 60 – 70% with onset within 15 – 30 minutes; subcutaneous bioavailability is higher (approximately 85 – 95%) with somewhat slower onset. Selank is not a cytochrome P450 (CYP, a family of liver enzymes that metabolizes many drugs) substrate and is cleared by proteolysis. Distribution includes plasma, cerebrospinal fluid, and central nervous system tissue with penetration across the blood-brain barrier.

Historical Context & Evolution

  • 1970s: Tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide derived from the Fc region of immunoglobulin G, was first characterized by Victor Najjar and colleagues at Tufts University as a natural enhancer of phagocytosis (the process by which immune cells engulf pathogens) and innate immunity. This opened the field of immunomodulatory peptides.
  • 1980s – 1990s: Researchers at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences, led by Nikolay Myasoedov, developed stabilized tuftsin analogs. Adding the Pro-Gly-Pro tripeptide extended plasma half-life from seconds to minutes and added anxiolytic and nootropic effects not present in tuftsin, producing the heptapeptide later named Selank (also designated TP-7).
  • 2000s: Extensive preclinical work at IMG and the V.V. Zakusov Scientific Research Institute of Pharmacology characterized Selank’s anxiolytic, nootropic, and immunomodulatory properties, reporting efficacy comparable to benzodiazepines in animal anxiety models without sedation, memory impairment, or dependence.
  • 2008: Zozulia and colleagues published a landmark comparative clinical trial of Selank versus the benzodiazepine medazepam in 62 patients with generalized anxiety disorder and neurasthenia (a historical term referring to a fatigue- and anxiety-predominant syndrome), reporting comparable anxiolytic efficacy with additional anti-fatigue and mild activating effects and no benzodiazepine-type side effects.
  • 2009: Selank received regulatory approval in Russia for generalized anxiety disorder as a 0.15% intranasal spray, marketed by NPO Peptogen under IMG supervision. Ershov and colleagues separately characterized antiviral activity against influenza and other viruses via IFN-α induction.
  • 2014: Medvedev and colleagues published a comparative trial of Selank versus the Russian benzodiazepine phenazepam in 60 patients with phobic-anxiety and somatoform disorders, again showing comparable anxiolytic efficacy with better tolerability and a one-week carry-over of anxiolytic effect after discontinuation.
  • 2016 – 2020: Molecular mechanism studies by Volkova, Vyunova, Filatova, and colleagues mapped Selank’s effects on GABA-A subunit and transporter gene expression, while the Panikratova et al. functional MRI study provided the first human neuroimaging evidence of Selank’s effects on brain network connectivity.
  • Present: Selank remains approved only in Russia. It has not undergone U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) review. In the West it is available primarily through licensed compounding pharmacies on a physician-directed basis and through “research use only” peptide suppliers, and it has gained visibility in peptide-therapy and nootropic communities. Subsequent work on analogs such as N-acetyl Selank amidate (a chemically modified variant with longer half-life) remains preclinical.

Expected Benefits

Medium 🟩 🟩

Anxiolytic Effect (Reduction of Anxiety Symptoms)

Multiple Russian clinical trials in patients with generalized anxiety disorder (GAD) and related conditions have shown Selank reduces anxiety comparably to benzodiazepines without their sedative or dependence-forming profile. In the Zozulia et al. (2008) trial, 62 patients with GAD and neurasthenia received intranasal Selank or oral medazepam; both produced similar reductions on the Hamilton Anxiety Rating Scale (HARS, a clinician-administered anxiety severity scale), the Zung Self-Rating Anxiety Scale, and the Clinical Global Impression (CGI) scale, with Selank additionally showing anti-fatigue and mild activating effects. In the Medvedev et al. (2014) trial, 60 patients with phobic-anxiety and somatoform disorders (conditions in which psychological distress manifests as unexplained physical symptoms) received Selank or phenazepam, with comparable anxiolytic effects and a persistent one-week carry-over after Selank discontinuation. Across the trials, around 40% of patients were rapid responders whose HARS scores fell from approximately 20 to 7 within 1 – 3 days. Crucially, Selank did not produce sedation, muscle relaxation, tolerance, dependence, or withdrawal — the main liabilities of benzodiazepine comparators. The evidence base is consistent but small (fewer than 200 patients total) and entirely Russian, without independent international replication.

Magnitude: Comparable anxiety reduction to benzodiazepines (medazepam, phenazepam) on HARS, Zung, and CGI; approximately 40% rapid-response rate with HARS reduction from about 20 to about 7 within 1 – 3 days; anxiolytic effect persisting roughly one week after discontinuation.

Low 🟩

Nootropic Effect (Cognitive Enhancement)

The Medvedev et al. (2014) clinical trial reported mild cognitive-enhancing effects alongside Selank’s anxiolytic activity in patients with anxiety disorders, most prominently on tests of attention and information processing. Animal work provides stronger mechanistic support: Selank upregulates BDNF expression in the hippocampus and prefrontal cortex and improves performance on memory and active-avoidance tasks. Kolik et al. (2019) reported that Selank (0.3 mg/kg/day for 7 days) produced cognitive enhancement in the object-recognition test and protected against ethanol-induced memory and attention deficits during alcohol withdrawal. Controlled human studies specifically evaluating cognitive enhancement in healthy individuals without anxiety are not available.

Magnitude: Not quantified in available studies.

Immunomodulation and Anti-Inflammatory Effects

Selank modulates expression of over 35 inflammation-related genes in the spleen (Kolomin et al., 2011) and, under chronic social stress in rodents, reduces pro-inflammatory IL-1β, IL-6, and TNF-α while restoring IL-4 toward baseline (Yasenyavskaya et al., 2021). The Uchakina et al. (2008) study in patients with anxiety-asthenic disorders found that Selank modulated Th1/Th2 balance (the ratio between two arms of the adaptive immune system, T-helper type 1 and type 2 responses) over 14 days of treatment. These effects are of interest for long-term health but have been demonstrated mostly in animal models or in patients with psychiatric disorders rather than in healthy adults seeking immune optimization.

Magnitude: Not quantified in available studies.

Stress-Protective Effects

Animal studies show that Selank protects against the physiological consequences of chronic stress. Fomenko et al. (2017, 2019) reported that Selank normalized hepatic morphological and functional changes produced by foot-shock and restraint stress. Kasian et al. (2017) found in the elevated plus maze that Selank reduced anxiety induced by chronic unpredictable mild stress, with the combination of Selank and diazepam most effective under chronic-stress conditions. Human evidence for stress-protective effects is indirect and derived from the anxiety-disorder clinical trials.

Magnitude: Not quantified in available studies.

Speculative 🟨

Antiviral Activity

Preclinical work reports pronounced antiviral effects. Ershov et al. (2009) showed complete suppression of influenza A (H3N2) replication in cell culture when Selank was applied preventively 24 hours before inoculation, and improved survival in infected animals; the proposed mechanism is IFN-α gene induction and modulation of Th1/Th2/Treg balance (the addition of regulatory T cells, a T-cell subset that dampens immune responses). Andreeva et al. (2010) reported antiviral activity of structural fragments of Selank against encephalomyocarditis virus. All findings are in vitro or in animals; no human antiviral trials exist.

Neuroprotection

Selank’s BDNF upregulation, multi-system neurotransmitter modulation, reduction of neuroinflammation, and protection against ethanol-induced memory impairment collectively suggest neuroprotective potential. Slominsky et al. (2017) reported behavioral effects of Selank in a 6-OHDA (6-hydroxydopamine, a neurotoxin that destroys dopaminergic neurons) rat model of Parkinson’s disease, and the Panikratova et al. (2020) fMRI study showed rapid changes in human brain connectivity. No human neurodegenerative trials have been conducted.

Antidepressant Effect

Sarkisova et al. (2008) described antidepressant-like effects of Selank in genetically vulnerable WAG/Rij rats and BALB/c mice in behavioral models of depression and anhedonia (reduced capacity to experience pleasure). Clinical trials in anxiety disorders noted secondary improvements in mood, but no controlled human trial has evaluated Selank specifically as an antidepressant.

Anti-Addiction Properties

Selank reduced ethanol-induced hyperlocomotion and behavioral sensitization in mice (Kolik et al., 2016), protected against ethanol-induced memory impairment (Kolik et al., 2019), and attenuated morphine-withdrawal signs in rats (Konstantinopolsky et al., 2022). These preclinical findings are suggestive for addiction-related applications but have no human counterpart.

Benefit-Modifying Factors

  • Baseline anxiety level: Clinical trial data consistently show that those with diagnosed anxiety disorders (GAD, phobic-anxiety, somatoform) derive the most measurable benefit; individuals with lower baseline anxiety typically experience subtler effects. The approximately 40% rapid-response rate was specifically in clinically diagnosed populations.
  • Genetic polymorphisms: Variants in GABA-A receptor subunit genes — for example GABRG2 and GABRA2, which encode structural components of the GABA-A receptor — could theoretically modulate responsiveness to Selank’s allosteric action, though this has not been formally tested. Polymorphisms in BDNF (such as the Val66Met variant, which alters activity-dependent BDNF secretion and is linked to anxiety susceptibility) are another plausible modifier.
  • Sex-based differences: Published trials enrolled men and women but have not reported sex-stratified analyses; no sex-dependent differences in efficacy have been identified.
  • Pre-existing health conditions: Individuals with autoimmune disease, active cancer, or other conditions involving immune dysregulation may respond differently given Selank’s broad cytokine effects; those with pre-existing mood disorders beyond anxiety may likewise experience atypical responses.
  • Age-related considerations: Trials enrolled adolescents through middle-aged adults (roughly 18 – 55). Older adults might be expected to benefit from Selank’s stress-protective and immunomodulatory effects in the context of age-related immune decline (immunosenescence) and neurodegeneration, but have not been specifically studied; the Uchakina et al. (2008) group proposed adaptogenic utility in the elderly based on their immune findings.
  • Baseline biomarker levels: Individuals with elevated inflammatory markers or abnormal cytokine balance may respond with more pronounced immunomodulatory shifts, but no clinical evidence directly validates this.

Potential Risks & Side Effects

Medium 🟥 🟥

Immunogenicity Risk (Compounded and Research-Grade Preparations)

The U.S. FDA has specifically flagged compounded synthetic peptides — including Selank — as carrying potential immunogenicity concerns. Immunogenicity here means the body’s ability to mount an immune response against the peptide or contaminants, ranging from mild injection-site reactions to severe allergic responses. The risk is strongly tied to preparation quality: compounded and research-grade products vary widely in purity, sterility, and endotoxin content. The clinical trial record (conducted on pharmaceutical-grade Russian product) does not describe significant immunogenicity, but the trials did not systematically screen for anti-peptide antibodies and are not generalizable to products made under less-controlled conditions.

Magnitude: Not quantified in available studies.

Limited Long-Term Safety Data

Selank clinical trials have been short — typically 14 days of active treatment — and have not formally followed patients beyond approximately one week of carry-over. No trials have assessed chronic use over months or years, which matters particularly for a longevity-oriented adult considering extended or repeated cycles. This is an evidence gap rather than a signal of harm, but it is a meaningful one.

Magnitude: Not quantified in available studies.

Low 🟥

Mild Local Reactions (Intranasal Administration)

Some users report mild nasal stinging, dryness, or irritation with intranasal administration. These effects are typically transient and resolve without intervention; clinical trials did not identify statistically significant differences in local adverse events between Selank and comparator.

Magnitude: Mild, transient nasal discomfort reported anecdotally; no significant local adverse events versus comparator in clinical trials.

Mild Systemic Symptoms (Headache, Fatigue, Dizziness)

Infrequent reports of mild headache, fatigue, or dizziness have been noted in user reports and in clinical practice, typically at higher doses or early in treatment, but have not been reported at frequencies distinguishable from placebo in the published trials.

Magnitude: Reported infrequently; not statistically distinguishable from placebo or active comparator in clinical trials.

Speculative 🟨

Unpredictable Immune Modulation

Given Selank’s documented ability to alter expression of over 35 inflammation-related genes and to shift Th1/Th2 balance, there is a theoretical risk of unpredictable immune effects in individuals with autoimmune conditions, immune dysregulation, or concurrent immunomodulatory therapy. This has not been observed in controlled trials but is a reasonable concern given the breadth of the peptide’s immunological activity.

Potentiation of GABAergic Medications

As a positive allosteric modulator of GABA-A receptors, Selank could theoretically potentiate the effects of other GABAergic substances (benzodiazepines, barbiturates, alcohol). The Kasian et al. (2017) animal study showed combined Selank-and-diazepam effects distinct from either alone, confirming pharmacological interaction. The clinical significance of such interactions in humans at therapeutic doses has not been formally characterized.

Unstudied Effects in Cancer and Pregnancy

Given the immunomodulatory activity and the absence of reproductive or oncology safety data, use in pregnancy, breastfeeding, or active cancer is an open risk category rather than a demonstrated harm; the prudent default in evidence reviews is to treat these populations as contraindicated.

Risk-Modifying Factors

  • Source and purity: The most important modifiable factor is product quality. Compounded or research-grade Selank from unregulated suppliers may contain peptide-related impurities, synthesis byproducts, residual solvents, or endotoxin — all of which drive immunogenicity and injection-reaction risk. Pharmaceutical-grade product, or compounded product with a third-party certificate of analysis (COA) showing high-performance liquid chromatography (HPLC) purity ≥98% and low endotoxin, substantially reduces this risk.
  • Genetic polymorphisms: Individuals with HLA variants (human leukocyte antigen genes that regulate immune recognition of self versus foreign) associated with drug hypersensitivity may face higher immunogenicity risk; this has not been studied for Selank specifically. GABA-A receptor subunit polymorphisms (GABRG2, GABRA2) are of theoretical interest for tolerability rather than risk per se.
  • Baseline biomarker levels: Individuals with abnormal cytokine profiles, elevated inflammatory markers, or autoantibody positivity are most likely to show unexpected immune shifts and warrant closer monitoring.
  • Sex-based differences: No sex-based differences in adverse effects have been identified in the limited clinical trial data.
  • Age-related considerations: Older adults with declining immune regulation may be more sensitive to unpredictable immunomodulatory effects, and age-related reductions in kidney or liver function could theoretically alter peptide exposure. Starting low and titrating cautiously is appropriate.
  • Pre-existing health conditions: Autoimmune disease, active infection requiring immunosuppression, concurrent immunomodulatory biologic therapy, and active cancer define the highest-risk profile. Concurrent GABAergic medication (benzodiazepines, gabapentinoids, barbiturates) adds potential additive central nervous system depression.

Key Interactions & Contraindications

  • Benzodiazepines: Confirmed pharmacological interaction at the GABA-A receptor (caution; clinical consequence: potentially additive anxiolytic and sedative effects; under chronic stress, Kasian et al. (2017) showed augmented anxiolysis from combined Selank and diazepam, while the profile under non-stress differed). Named examples include diazepam, alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), and phenazepam. Concurrent use requires medical supervision and a dose-reduction or timing-separation plan.
  • Other GABAergic drugs: Theoretical additive central nervous system depression (caution) with gabapentinoids (gabapentin, pregabalin), barbiturates (phenobarbital), and the “Z-drugs” (zolpidem, eszopiclone, zaleplon).
  • Alcohol: Avoidance or strict moderation is advised (caution; clinical consequence: additive central nervous system depression, unpredictable anxiolytic-sedative interaction). Preclinical data specifically show Selank modulates alcohol-related behaviors.
  • Over-the-counter medications: Sedating antihistamines (diphenhydramine, doxylamine) and OTC sleep aids have GABAergic or anticholinergic effects that could theoretically produce additive CNS depression with Selank (caution). OTC analgesics (acetaminophen, ibuprofen, naproxen) are not expected to interact.
  • SSRIs and SNRIs: Theoretical additive serotonergic effects (caution; clinical consequence: low-probability risk of serotonin syndrome — a potentially dangerous state of excessive serotonergic activity characterized by agitation, hyperthermia, and neuromuscular hyperactivity — with selective serotonin reuptake inhibitors [SSRIs; fluoxetine, sertraline, escitalopram] or serotonin-norepinephrine reuptake inhibitors [SNRIs; venlafaxine, duloxetine]). No clinical cases have been reported, but serotonergic modulation makes the theoretical risk non-zero.
  • Immunosuppressive medications: Unpredictable interactions (caution; clinical consequence: possible attenuation or exaggeration of immune effects) with corticosteroids (prednisone, methylprednisolone), calcineurin inhibitors (cyclosporine, tacrolimus), and biologic immunomodulators (infliximab, adalimumab, rituximab).
  • Supplements known to have additive effects: GABAergic and calmative supplements (phenibut, L-theanine, valerian, kava, magnesium glycinate, taurine) may have additive anxiolytic effects with Selank (caution). The related Russian peptide Semax (a synthetic fragment of ACTH, adrenocorticotropic hormone) has been co-administered with Selank in Russian clinical practice and may have complementary rather than additive effects.
  • Populations who should avoid Selank:
    • Pregnant or breastfeeding individuals — absolute contraindication (no reproductive safety data).
    • Children and adolescents under 18 — absolute contraindication (no pediatric safety data).
    • Active cancer of any type, or cancer within the past 5 years — absolute contraindication (immunomodulatory effects are unpredictable).
    • Active, untreated autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis) — absolute contraindication pending specialist input (risk of immune dysregulation).
    • Known hypersensitivity to synthetic peptides — absolute contraindication.
    • Concurrent use of high-dose or multiple GABAergic drugs without supervision — contraindicated without a specific clinician-managed plan.
    • Severe hepatic impairment (Child-Pugh Class C, a classification of end-stage liver disease) or severe renal impairment (estimated glomerular filtration rate [eGFR, a measure of kidney filtration capacity] <30 mL/min/1.73m²) — caution with dose reduction and close monitoring.
  • Mitigating actions: Dose reduction and timing separation from other GABAergic drugs; adherence to the lowest effective dose; avoidance of alcohol on dosing days; and use only of product with third-party COA showing identity, purity ≥98%, and low endotoxin.

Risk Mitigation Strategies

  • Source verification with third-party certificates of analysis: To mitigate immunogenicity and contaminant risk, use only product from licensed compounding pharmacies operating under cGMP (current Good Manufacturing Practice, the regulatory quality standard for pharmaceutical manufacturing) or research vendors that publish third-party COAs documenting identity (by HPLC and mass spectrometry), purity ≥98%, endotoxin <0.5 EU/mg, and sterility for injectable preparations.
  • Start-low, go-slow dosing: To mitigate tolerability issues such as mild headache, fatigue, or local irritation, begin at the lower end of the literature-reported range (for example 200 – 250 mcg intranasally or subcutaneously per dose) and hold for several days before any upward titration.
  • Short initial cycles with washout: To mitigate the unknown long-term safety profile, limit initial use to 14 – 28 days (consistent with clinical trial durations) followed by an equal-length washout period during which delayed adverse effects can be observed. Practitioner cycling patterns commonly use 2 – 4 weeks on / 2 – 4 weeks off thereafter.
  • Avoid combining with GABAergic substances without supervision: To mitigate additive CNS depression, do not combine Selank with benzodiazepines, alcohol, gabapentinoids, or sedating antihistamines without a clinician’s dose plan.
  • Immune-marker monitoring for extended use: To mitigate unpredictable immune modulation, obtain a complete blood count (CBC) with differential and a high-sensitivity C-reactive protein (hsCRP, a systemic inflammation marker) at baseline and repeat every 4 – 8 weeks during active cycles; thyroid-stimulating hormone (TSH) and basic autoantibody screening should be considered if extended cycles are planned.
  • Discontinuation around surgery or vaccination: To mitigate unpredictable immune modulation around immunologically sensitive events, discontinue Selank at least 3 – 5 days before any elective surgical procedure or vaccination; this is a precaution rather than an evidence-based mandate.
  • Sterile reconstitution and cold-chain storage: To mitigate bacterial contamination and peptide degradation, reconstitute lyophilized (freeze-dried) Selank with bacteriostatic water (0.9% benzyl alcohol-preserved), refrigerate reconstituted solution at 2 – 8 °C, protect from light, and discard within 28 days; rotate injection sites where applicable.
  • Morning/early-afternoon dosing: To mitigate potential interference with sleep onset from Selank’s mild activating effects, restrict dosing to morning and early afternoon rather than evening.
  • Physician awareness: To mitigate the risk of operating fully outside a clinical relationship, engage a physician familiar with peptide therapy for ongoing oversight, particularly when combining with any concurrent medication affecting GABAergic, serotonergic, or immune signaling.

Therapeutic Protocol

Russian clinical trials and the approved intranasal formulation provide the most defensible protocol framework. Western peptide-therapy practice has extended this in two main directions: subcutaneous injection for greater bioavailability, and cycled use for long-term safety.

  • Standard anxiolytic protocol (intranasal): The approved Russian product is a 0.15% nasal spray, administered 2 – 3 times daily. In typical clinical use this corresponds to approximately 200 – 400 mcg per nostril per dose, for a total daily dose of roughly 400 – 2400 mcg. The Zozulia et al. (2008) trial administered Selank over 14 days; 14 – 28 days is the most commonly referenced treatment cycle.
  • Alternative protocol (subcutaneous injection): Used in research and in Western peptide practice. Typical doses range from 250 – 500 mcg once daily subcutaneously. Subcutaneous administration achieves approximately 85 – 95% bioavailability (versus 60 – 70% intranasal), with slower onset (30 – 60 minutes versus 15 – 30 minutes intranasal).
  • Competing approaches and clinic origins: The Institute of Molecular Genetics and the V.V. Zakusov Institute of Pharmacology established the intranasal protocol — both Russian state-supported institutions with a direct institutional interest in Selank’s adoption. Western peptide-therapy practitioners — including those in the American Academy of Anti-Aging Medicine (A4M, a medical organization focused on age-management medicine) orbit and writers such as Jay Campbell — popularized the subcutaneous variant. A4M’s membership derives direct revenue from prescribing and administering peptide therapies, so its advocacy in favor of subcutaneous peptide protocols is itself a source of potential bias. Neither Russian-institutional nor A4M-aligned framing is adopted as a universal default in this review.
  • Best time of day: Morning and early afternoon. Selank’s mild activating and nootropic properties argue against late-evening dosing, though it does not cause the insomnia characteristic of classical stimulants.
  • Half-life and dosing rationale: Plasma half-life is short (approximately 2 – 10 minutes), but functional anxiolytic and nootropic effects persist for 12 – 24 hours because of downstream gene-expression, neurotrophic, and receptor-modulation changes that outlast direct peptide exposure.
  • Single vs. split dosing: Split dosing (2 – 3 times daily for intranasal; typically once daily subcutaneous) is preferred over a single bolus to maintain consistent functional effect, reflecting both the short plasma half-life and the 14-day trial protocols in which split dosing was the norm.
  • Genetic polymorphisms: No pharmacogenomic guideline exists for Selank dosing. GABA-A subunit polymorphisms (GABRG2 variants associated with altered benzodiazepine sensitivity) and the BDNF Val66Met variant (which affects activity-dependent BDNF secretion) are plausible modifiers of response but have no validated protocol implications.
  • Sex-based differences: No sex-specific dosing has been established.
  • Age-related considerations: Trials enrolled adults aged roughly 18 – 55. For older adults, starting at the low end of the range and titrating slowly is appropriate given possible reductions in peptide clearance and potentially greater sensitivity to GABAergic modulation.
  • Baseline biomarker levels: Higher baseline anxiety (HARS above approximately 17) predicted more pronounced clinical response in the Russian trials; those with lower baseline anxiety typically experience subtler effects.
  • Pre-existing health conditions: Individuals with hepatic or renal impairment should start at lower doses; those with autoimmune conditions should use Selank only under close medical supervision with baseline and follow-up immune monitoring.

Discontinuation & Cycling

  • Lifelong vs. short-term: Selank is positioned as an intermittent therapy rather than a lifelong one. Russian clinical trials defined 14-day treatment courses; Western practitioner use most commonly extends this to 14 – 28 days per cycle. There is no evidence supporting indefinite continuous use, and the absence of long-term safety data argues against it.
  • Withdrawal effects: A distinguishing feature of Selank compared with benzodiazepines is the absence of a withdrawal syndrome. Medvedev et al. (2014) specifically noted that the anxiolytic effect persisted for approximately one week after the last dose with no rebound anxiety or discontinuation symptoms.
  • Tapering: Not required. Selank can be discontinued abruptly; no withdrawal, rebound, or discontinuation syndrome has been reported in any published trial.
  • Cycling: The most common Western practitioner pattern is 2 – 4 weeks on followed by 2 – 4 weeks off, with some protocols using a shorter 5-days-on / 2-days-off structure within a cycle. The rationale is precautionary — limiting total exposure to an unvalidated long-term compound and allowing assessment of sustained effects — rather than evidence-based. Tachyphylaxis (diminishing response with repeated dosing) has not been formally documented for Selank.

Sourcing and Quality

Selank is not a dietary supplement in any jurisdiction. Outside of Russia it is supplied either by licensed compounding pharmacies on a physician-directed basis or by “research use only” (RUO) peptide vendors that are not subject to pharmaceutical quality standards. Sourcing choices have an outsized effect on safety.

  • Pharmaceutical-grade (Russia): The only regulator-approved product is the NPO Peptogen 0.15% intranasal spray, manufactured under Russian pharmaceutical Good Manufacturing Practice (GMP) standards and supervised by the Institute of Molecular Genetics.
  • Licensed compounding pharmacies (Western): Outside Russia, the cleanest accessible path is a U.S. 503A or 503B compounding pharmacy, or equivalent regulated pharmacies in other jurisdictions, preparing Selank as an intranasal solution or a lyophilized powder for subcutaneous injection under a physician prescription. Quality varies between pharmacies — a third-party certificate of analysis (COA) is the key differentiator.
  • Research-use peptide suppliers: Many online vendors sell Selank as “research use only.” Quality control is highly variable, and immunogenicity and contaminant risk is materially higher than with compounding pharmacy product.
  • Third-party testing — quality markers to verify: HPLC purity ≥98% with correct retention profile; mass spectrometry confirmation of the Selank molecular weight (approximately 751.9 Da); sterility testing for any injectable preparation; endotoxin testing by LAL assay (Limulus amebocyte lysate, a standard bacterial-endotoxin test); and documented cold-chain storage and shipping.
  • Storage and stability: Store lyophilized Selank at −20 °C for long-term storage. After reconstitution with bacteriostatic water, refrigerate at 2 – 8 °C, protect from light, and use within 28 days. Nasal spray products should be refrigerated once opened.
  • Reputable brands and pharmacies: Examples frequently cited in peptide-therapy practice include licensed 503A and 503B compounders (e.g., Empower Pharmacy, Tailor Made Compounding) that prepare Selank under physician prescription, and research peptide vendors that publish third-party HPLC and endotoxin COAs (e.g., Peptide Sciences). Any named vendor requires re-verification at the time of use because regulatory stances and quality records change frequently.

Practical Considerations

  • Time to effect: Anxiolytic effects can be rapid — roughly 40% of clinical trial patients showed meaningful reductions within 1 – 3 days. For most users, clear anxiolytic effects emerge within 1 – 2 weeks. Nootropic benefits typically take longer (4 – 6 weeks reported), and immunomodulatory effects likely develop over a full 14 – 28 day cycle.
  • Common pitfalls: Frequent errors include buying from unverified RUO suppliers with no COA, expecting benzodiazepine-like immediate sedation (Selank’s calming effect is non-sedating and subtler), combining with benzodiazepines or alcohol without medical guidance, using continuously without cycling despite absent long-term safety data, improper storage of reconstituted peptide leading to degradation, and expecting dramatic cognitive enhancement in the absence of baseline anxiety (nootropic effects are most visible when anxiety is suppressing cognition).
  • Regulatory status: Selank is approved as a pharmaceutical drug in Russia for generalized anxiety disorder. It is not approved by the FDA, EMA, or other major Western regulators. In the United States it is not a controlled substance but the FDA has included Selank on lists of substances it considers to have compounding-safety concerns; access is primarily through compounding pharmacies with a physician prescription or through research suppliers.
  • Cost and accessibility: Selank is moderately priced relative to other therapeutic peptides. A 5 – 10 mg vial from a Western compounding pharmacy typically costs approximately $50 – $150 USD. The Russian pharmaceutical product is substantially less expensive but hard to obtain outside Russia. Research-grade product from online vendors is generally cheaper but carries higher quality risk, and any clinician oversight and laboratory monitoring adds to total cost.

Interaction with Foundational Habits

  • Sleep: Direction: indirect, net neutral to supportive. Selank does not suppress deep sleep or rapid eye movement (REM, the sleep phase important for memory consolidation and emotional processing) sleep architecture and is not a sedative; its anxiolytic effect may indirectly improve sleep in people whose sleep is disrupted by anxiety or rumination. Its mild activating properties argue against evening dosing — practical consideration: limit dosing to morning and early afternoon.
  • Nutrition: Direction: none established. No specific dietary interactions are known. Selank is a peptide of natural amino acids and does not require particular nutritional cofactors. It can be taken with or without food; intranasal administration works best on a relatively clear nasal passage, so timing around meals is a practical rather than biochemical consideration. No nutrient depletions have been reported.
  • Exercise: Direction: none established, possibly indirect-supportive. No controlled data describe interactions with training. Selank’s stress-protective and cortisol-modulating effects could in theory support recovery, and its nootropic activity might enhance focus during skill-based training, but these are speculative extensions of the preclinical record rather than observed effects. No timing restrictions relative to training sessions are documented.
  • Stress management: Direction: direct-supportive. Selank acts on core stress-regulation pathways — GABAergic, serotonergic, dopaminergic, and cytokine — with preclinical data showing protection against the physiological consequences of chronic stress (e.g., Fomenko et al., 2017, 2019, on stress-induced hepatic changes; Kasian et al., 2017, on chronic unpredictable mild stress). Practical consideration: Selank is likely to complement rather than replace foundational stress-management practices such as breathwork, meditation, regular aerobic activity, and sleep hygiene.

Monitoring Protocol & Defining Success

Because Selank is not an approved Western therapy, there is no officially endorsed clinical monitoring protocol. The framework below is drawn from the Russian trial record, general peptide-therapy practice, and the immunomodulatory and central nervous system profile of the compound; it is a reasonable evidence-informed starting point rather than a clinical recommendation.

Baseline testing (before starting): Obtain a baseline panel before the first dose to establish individual reference values. This should include immune and inflammatory markers (to detect any subsequent shift), basic metabolic function (liver and kidney), and — where available — validated anxiety or cognitive instruments for tracking response.

Ongoing monitoring cadence: During an active 14 – 28 day cycle, reassess qualitative markers weekly and repeat a complete blood count with differential and hsCRP at roughly the 4-week mark. For individuals using Selank in repeated cycles, repeat the full baseline panel every 3 – 6 months while dosing, and the qualitative measures weekly during each cycle.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Complete blood count with differential WBC 4.5 – 7.5 ×10⁹/L; lymphocytes 25 – 40% Establish immune baseline before an immunomodulatory peptide WBC = white blood cell count. Conventional range WBC 4.0 – 11.0 ×10⁹/L; no fasting required
hsCRP <1.0 mg/L Track baseline and on-cycle systemic inflammation hsCRP = high-sensitivity C-reactive protein; conventional clinical cut-off <3.0 mg/L; avoid measuring during acute illness
Comprehensive metabolic panel Within conventional range Liver and kidney safety relevant to peptide metabolism and clearance Includes electrolytes, creatinine, eGFR (estimated glomerular filtration rate, a measure of kidney function), liver enzymes; 8 – 12 hour fast for glucose accuracy
Fasting glucose 70 – 90 mg/dL General metabolic health baseline 8 – 12 hour fast; conventional reference 70 – 99 mg/dL
Cortisol (AM) 10 – 18 mcg/dL Stress-hormone baseline to track stress-protective effects Draw between 7 – 9 AM; conventional range 6 – 23 mcg/dL
TSH 0.5 – 2.5 mIU/L Thyroid function as part of broader endocrine baseline TSH = thyroid-stimulating hormone; conventional range 0.4 – 4.5 mIU/L
Standardized anxiety scale (GAD-7 or HARS) Score reduction relative to baseline Quantify clinical response where anxiety is a target GAD-7 = Generalized Anxiety Disorder 7-item scale; HARS = Hamilton Anxiety Rating Scale; administer weekly

Qualitative markers to track on a simple 1 – 10 self-rating weekly:

  • Anxiety level (generalized worry, situational anxiety, physical tension)
  • Cognitive clarity, focus, and short-term memory during the day
  • Stress resilience (capacity to manage ordinary daily stressors)
  • Sleep quality (ease of falling asleep, feeling rested)
  • Energy, motivation, and drive
  • Mood stability (emotional reactivity, irritability)
  • Injection-site reactions or nasal irritation
  • Any new or unusual symptoms (persistent rash, unexplained fatigue, infection signs)

Defining success: A reasonable definition of a successful response is a measurable reduction in anxiety symptoms where anxiety was a target (for example a ≥50% reduction on GAD-7 or HARS, consistent with the Russian trial outcomes), improved subjective cognitive clarity and stress resilience on the qualitative scale, and stable or improved immune markers. Any rise in inflammatory markers, unexplained cytopenias on CBC, or new persistent symptoms should trigger discontinuation and re-evaluation.

Emerging Research

Selank-related clinical research remains heavily concentrated in Russia and is dominated by observational and mechanistic work rather than new interventional trials. A few themes define the current frontier:

Key unresolved questions include: (1) whether the Russian anxiolytic findings replicate in independently conducted international trials; (2) whether long-term (months-to-years) use is safe from an immunogenicity and immune-modulation standpoint; and (3) whether the preclinical antiviral, neuroprotective, and addiction-related signals translate to humans.

Conclusion

Selank is a short synthetic peptide with a distinctive profile: consistent anxiety-reduction in small Russian clinical trials comparable to standard anti-anxiety medications, but without the sedation, tolerance, dependence, or withdrawal that limit those medications as long-term tools. The underlying biology — calming modulation of the brain’s main inhibitory neurotransmitter system, support for nerve-growth signaling, modulation of mood-related brain chemistry, and broad immune-signaling effects — is well characterized at the molecular level and plausibly aligns with the clinical observations.

The important caveats are structural. The clinical evidence base is small, geographically concentrated, and has not been independently replicated outside Russia. Long-term safety data are absent. The peptide is approved only in Russia, the U.S. Food and Drug Administration has flagged compounded peptides for immune-response concerns, and product quality varies widely. Nearly all primary evidence comes from a small cluster of Russian institutions (including the Institute of Molecular Genetics and the manufacturer NPO Peptogen) with a direct institutional interest in adoption, and Western advocacy for the subcutaneous route is concentrated in peptide-therapy practitioner groups whose members derive direct revenue from such protocols.

For a longevity-oriented adult, the most defensible reading is that Selank appears to be a calming, cognition-preserving, and immune-modulating peptide with a favorable short-term safety profile in the published record, but with an evidence base too narrow and too conflicted at the source to support strong claims. Its risk-benefit profile is highly sensitive to source quality, concurrent medications, and individual health context.

Top - Benefits - Risks - Protocol